Impact of estradiol structural modifications (18-methyl and/or 17-hydroxy inversion of configuration) on the in vitro and in vivo estrogenic activity

It is well recognized that the majority of breast cancers are initially hormone-dependent and that 17 beta-estradiol (17 beta-E2) plays a crucial role in their development and progression. For this reason, using a compound able to block a specific enzyme involved in the last steps of the biosynthesis of 17 beta-E2 remains a rational way to treat estrogen-dependent diseases such as breast cancer. The present study describes the biological in vitro and in vivo evaluation of a structural modification (inversion of C18-methyl group at position 13 from beta to alpha face) of 17 beta-E2 (1) and 17 alpha-estradiol (17 alpha-E2; 2). The two epimers 18-epi-17 beta-E2 (3) and 18-epi-17 alpha-E2 (4) were obtained in two chemical steps by inversion of the C18-methyl of estrone using 1,2-phenylendiamine in refluxing acetic acid and reduction of ketone at position C17 with LiAlH4. The new E2 isomers were tested on estrogen-sensitive cell lines (MCF-7 and T-47D), on estrogen-sensitive tissues (uterus and vagina of mice) and on estrogen receptor (ER) to determine their estrogenic potency relatively to natural estrogen 17 beta-E2 (1). The results show that 18-epi-17 beta-E2 (3) possesses the lower affinity for ER (RBA = 1.2%), the lower estrogenicity on estrogen-sensitive cells (1000 folds less estrogenic than 17 beta-E2 in MCF-7) and no uterotrophic (estrogenic) activity when tested on mice. In fact, we observed the following order of estrogenicity: 18-epi-17 beta-E2 (3) < 18-epi-17 alpha-E2 (4) < 17 alpha-E2 (2) << 17 beta-E2 (1). These results suggest that the inversion of C18-methyl of natural 17 beta-E2 scaffold could be a useful strategy to decrease the estrogenicity of E2 derivatives used as enzyme inhibitors in the context of a treatment of estrogen-dependent diseases. (C) 2011 Elsevier Ltd. All rights reserved.